Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

Queer Eye star Jonathan Van Ness emphasized his stance on body positivity after fans had a "gigantic conversation" about how ...

While citrus aurantium may have fewer side effects and be easier to obtain than prescription diet pills, I think the risk, cost and lack of clear benefit of supplements containing this compound do not ...

Pharmaceutical company Novo Nordisk is working on an Ozempic-style semaglutide tablet just for weight loss, and early results ...

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

GLP-1 medications have been a life-changing tool to help people manage their blood sugar and lose weight. But the most popular forms of these medications have a big drawback: you have to inject ...

A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike ...

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy. The Eli Lilly drug, called ...

This could really move the needle in the GLP-1 weight loss market. Semaglutide, the active ingredient in Ozempic and Wegovy, is injected into the fatty tissue just under the skin of the stomach, thigh ...

A pill form of the weight loss drug Wegovy was as effective as injections for people with obesity in a clinical trial, the drug's manufacturer said. Novo Nordisk said in its news release that ...